EP2874504A1 - Method for the degradation of keratin and use of the keratin hydrolysate produced - Google Patents

Method for the degradation of keratin and use of the keratin hydrolysate produced

Info

Publication number
EP2874504A1
EP2874504A1 EP13739699.0A EP13739699A EP2874504A1 EP 2874504 A1 EP2874504 A1 EP 2874504A1 EP 13739699 A EP13739699 A EP 13739699A EP 2874504 A1 EP2874504 A1 EP 2874504A1
Authority
EP
European Patent Office
Prior art keywords
keratin
protease
sequence
present
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13739699.0A
Other languages
German (de)
English (en)
French (fr)
Inventor
Shukun Yu
Charlotte Horsmans Poulsen
Jon Gade HANSTED
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DuPont Nutrition Biosciences ApS
Original Assignee
DuPont Nutrition Biosciences ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Nutrition Biosciences ApS filed Critical DuPont Nutrition Biosciences ApS
Publication of EP2874504A1 publication Critical patent/EP2874504A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/14—Pretreatment of feeding-stuffs with enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/20—Animal feeding-stuffs from material of animal origin
    • A23K10/26—Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry

Definitions

  • the present invention relates to methods and uses of a combination a protease and a non-sulphur containing surfactant in the degradation of keratin and subsequent uses of the keratin hydrolysate produced.
  • Keratin is the collective name for a family of tough proteins which are found in a number of structures. It is a protein used by numerous groups of animals as a structural element, and is a classic example of a fibrous protein. To fulfil this structural function, Keratin molecules are helical and fibrous, twisting around each other to form strands called intermediate filaments. It is thought that this makes a lot of the protein inaccessible to enzyme digestion at first instance. Additionally, keratin proteins contain a high percentage of sulfur-containing amino acids, largely cysteine, which form disulfide bridges between the individual molecules and assist in forming the fairly rigid structure of keratin. Unfortunately, the disulphide bridges also make digestion and degradation of the keratin rather difficult.
  • keratin There are two main types of keratin, alpha- and beta-keratins.
  • the a-keratins are mostly present in the hair (including wool), horns, nails, claws and hooves of mammals.
  • the harder ⁇ -keratins are found in nails and in the scales and claws of reptiles, their shells (Testudines, such as tortoise, turtle, terrapin), and in the feathers, beaks, claws of birds and quills of porcupines, ⁇ -keratins are formed primarily in beta sheets, although some beta sheets are also found in a-keratins.
  • the degradation of keratin can be of significant commercial value.
  • feathers One source of keratin in particular - feathers - is produced in vast quantities by the poultry industry. In 2002 approximately 49 billion chickens were utilized in the poultry industry. Poultry feathers typically contain approximately 90% protein in the form of ⁇ -keratin. However, keratin must be cleaved before its protein content can be digested by animals (McCasland and Richardson 1966, Poult. Sci., 45:1231 -1236; Moran et al.). Degradation of feathers can therefore provide an inexpensive source of digestible protein and amino acids. Accordingly feather hydrolysate (i.e. degraded feathers) can be utilized in a numbers of ways, such as in animal feed.
  • Degradation of keratin can be achieved by steam hydrolysis, chemical hydrolysis and enzyme hydrolysis.
  • steam hydrolysis is disclosed in M.J. Considine, 2000, NEW ENZYME TECHNOLOGIES FOR POULTRY BY-PRODUCTS. Proc. Aust. Poult. Sci.Sym. 2000...12, pages 163-165, ISSN No. 1034-6260).
  • One disadvantage of steam hydrolysis is that the process can degrade heat sensitive amino acids thereby depleting the nutritional content of the resultant feather hydrolysate.
  • the feather hydrolysate produced by steam hydrolysis has a relatively low digestibility. This is clearly undesirable for the use of the feather hydrolysate in feed as the amount of protein and amino acids available to the animal is suboptimal.
  • Another method to degrade keratin is chemical hydrolysis.
  • acids such as hydrochloric acid, alkalis such as sodium hydroxide and oxidants such as peracid can be used to breakdown the disulfide linkages present in keratin.
  • alkalis such as sodium hydroxide
  • oxidants such as peracid
  • One disadvantage of chemical hydrolysis is that the costs of the use of such chemicals can be expensive.
  • Another disadvantage is that the amount of amino acids may be reduced compared to enzymatic methods - see Kim et al. (Poultry Science, 2002, 85:95-98 - Table 2).
  • a further serious disadvantage is that many of the agents suggested for use in chemical hydrolysis are sulphur-containing agents unsuitable for food use (for example, sodium dodecyl sulfate (SDS), dithiothreitol (DTT), mercaptoethanol, L-cysteine, sodium sulphite, ammonium sulfamate and dimethylsulfoxide (DMSO)).
  • SDS sodium dodecyl sulfate
  • DTT dithiothreitol
  • mercaptoethanol L-cysteine
  • sodium sulphite sodium sulphite
  • ammonium sulfamate ammonium sulfamate
  • DMSO dimethylsulfoxide
  • a further method of degrading keratin is by enzymatic hydrolysis.
  • a number of patents Shih et al. granted in the name of North Carolina State University relate to the use of B. licheniformis PWD-1 or a keratinase isolated from this bacterium to degrade poultry feathers see, US 4,908,220, US 4,959,31 1 , US 5,063,31 1 , US 5,171 ,682, US 5,186,961 and US 5,712,147.
  • Enzyme degradation can be advantageous as some processes may result in more digestible protein and amino acids being present compared with the use of steam hydrolysis or chemical hydrolysis.
  • Cai et al. J. Zhejiang Univ. Sci. B 2008 9(9):713-720
  • a protease such as keratinase
  • Cai et al. discloses that sulphur-containing chemicals such as SDS, ammonium sulfatate and DMSO stimulated feather meal hydrolysis due to reactions caused by the sulphur-containing chemicals.
  • sulphur-containing chemicals such as SDS, ammonium sulfatate and DMSO stimulated feather meal hydrolysis due to reactions caused by the sulphur-containing chemicals.
  • sulphur-containing chemicals such as SDS, ammonium sulfatate and DMSO stimulated feather meal hydrolysis due to reactions caused by the sulphur-containing chemicals.
  • high levels of sulfites can provide potentially detrimental side-effects.
  • high levels of sulfite are linked with the aggravation of asthma in certain people and can be hazardous if used at high temperatures in industrial processes.
  • Fig. 1 shows the degradation of chicken feathers following reaction with (from left to right): 20 mg sodium bisulphite (K2), 150 ⁇ Protex 30L (E0); 150 ⁇ Protex 30L and 20mg sodium sulphite (E1 - 2 test tubes); and 150 ⁇ Protex 30L and 20mg sodium bisulphite (E2 - 2 test tubes).
  • Fig. 2 shows the degradation of chicken feathers following reaction with protease (Protex 30L) in the presence or absence of Grinsted® SSL P 55 VEG K-A (E481 , Sodium stearoyl lactate) and sodium sulphite. All tubes contain Protex 30L, in addition from left to right: test tubes 1 .0 and 1 .1 contain 20mg Grinsted® SSL and 20 mg Sodium sulphite; test tube 1 .2 contains 20 mg sodium sulphite and test tube 1 .3 contains 20 mg Grinsted® SSL .
  • Fig. 3 shows the amount of degradation of chicken feathers following reaction with protease (Protex 30L) in the presence or absence of Panodan® 517 KOSHER (E472e, diacetyltartaric acid esters of mono- and diglycerides) and Sodium sulphite. All tubes contain Protex 30L, in addition from left to right: test tubes 2.0 and 2.1 contain 20 mg Panodan® 517 and 20 mg Sodium sulphite, test tube 2.2. contains 20 mg Sodium sulphite and test tube 2.3 contains 20 mg Panodan® 517.
  • test tubes 2.0 and 2.1 contain 20 mg Panodan® 517 and 20 mg Sodium sulphite
  • test tube 2.2. contains 20 mg Sodium sulphite
  • test tube 2.3 contains 20 mg Panodan® 517.
  • Fig. 4 shows the keratin hydrolysis measured by absorbance following reaction of keratin material under various concentrations of protease Protex P.
  • Fig. 8 shows Sequence ID NO 1 Protex P
  • Fig. 9 showsSequence ID NO 2 Protex 6L
  • Fig. 10 shows Sequence ID NO 3
  • Fig. 11 shows Sequence ID NO 4
  • a seminal finding of the present invention is that non-sulphur containing surfactants can stimulate keratin degradation by proteases. This finding is particularly surprising as prior to the present invention it was generally believed that the presence of sulphur or the use of a reducing agent was key in stimulating keratin hydrolysis by proteases.
  • non-sulphur containing surfactants such as sodium stearoyl-2-lactylate and diacetyl tartartic acid esters of mono and diglycerides of fatty acids
  • keratin enhances the degradation and/or solubilisation of keratin by proteases.
  • This surprising finding allows keratin to be degraded and/or solubilized to provide, and/or keratin hydrolysate to be produced which has, a good source of digestible protein and amino acids.
  • the use of a non- sulphur containing surfactant in the enzymatic degradation of keratin may result in one or more of the following advantageous effects: i) a quicker process to achieve a desired level of degradation or a desired level of digestible protein and/or amino acids; ii) improved cost efficiencies in obtaining keratin hydrolysate with a desired level of digestible protein and/or source of amino acids; and/or iii) a reduction in the amount of the amount of sulphur containing chemicals utilized in the process.
  • the present invention provides a method of producing keratin hydrolysate comprising the step of i) admixing keratin material with a protease and a non-sulphur containing surfactant, optionally in a closed system or under controlled oxygen levels.
  • the present invention provides a method of degrading keratin wherein a keratin material is admixed with a protease and a non-sulphur containing surfactant.
  • the present invention provides a method of producing animal feed comprising admixing keratin hydrolysate produced by a method of the present invention with one or more animal feed constituents.
  • the present invention provides the use of a composition comprising a non-sulphur containing surfactant to stimulate enzymatic keratin degradation.
  • the composition comprising a non-sulphur containing surfactant may optionally comprise a protease.
  • the composition may be a pharmaceutical composition or a cosmetic composition.
  • the present invention provides use of keratin hydrolysate produced by the method of the present invention in feed.
  • the present invention provides keratin hydrolysate produced a method of the present invention.
  • the present invention provides a feed additive composition comprising the keratin hydrolysate of the present invention.
  • the present invention provides a feed comprising the keratin hydrolysate of the present invention.
  • the present invention relates to a method of degrading keratin or producing keratin hydrolysate comprising admixing a keratin material with a protease and a non-sulphur containing surfactant.
  • keratin hydrolysate refers to the resultant product following the hydrolysis of a keratin material by e.g. a protease.
  • the admixture may occur in a vessel or reactor.
  • the vessel or reactor is a free-fall vessel or reactor.
  • free-fall vessels include drum mixers and tumble mixers.
  • keratin material, one or more proteases and one or more surfactants may optionally be admixed (simultaneously or sequentially) with one or more further components.
  • the keratin material, protease and non-sulphur containing surfactant are admixed until a desired degree of degradation of the keratin material has occurred (e.g. until the digestibility of keratin material is increased, thereby enriching the concentration of digestible proteins and peptides therein).
  • a desired degree of degradation of the keratin material e.g. until the digestibility of keratin material is increased, thereby enriching the concentration of digestible proteins and peptides therein.
  • the optimal time period used will depend on a number of factors such as the temperature and pH in relation to the optimal pH and optimal temperature of the protease used; the degree of cross-linking present in the keratin material to be degraded; whether other components such as reducing agents, chemical oxidants, acids or alkalis are used in the process and the amount ratio of protease to keratin material for example.
  • the keratin material, protease and non-sulphur containing surfactant may be admixed for about 30 minutes to about 48 hours.
  • the keratin material and protease may be admixed from about 1 hour to about 42 hours; or from about 2 hours to about 36 hours; or from about 3 hours to about 30 hours; or from about 4 hours to about 24 hours; or from about 5 to about 18 hours.
  • the keratin material, protease and non-sulphur containing surfactant may be admixed for about 30 minutes to about 16 hours; or from about 30 minutes to about 14 hours; or from about 1 hour to about 12 hours; or from about 1 .5 hours to about 10 hours; or from about 2 hours to about 8 hours; or from about 3 to about 7 hours.
  • the keratin material, protease and non-sulphur containing surfactant may be admixed for at least 30 minutes; or at least 45 minutes; or at least 1 hour; or at least 1 .5 hours; or at least 2 hours; or at least 2.5 hours; or at least 3 hours; or at least 3.5 hours; or at least 4 hours; or at least 4.5 hours ;or at least 5 hours; or at least 5.5 hours; or at least 6 hours; or at least 7 hours; or at least 8 hours; or at least 9 hours; or at least 10 hours.
  • the keratin material, protease and non-sulphur containing surfactant is admixed for at least 2 hours.
  • the keratin material, protease and non-sulphur containing surfactant may be admixed for less than 16 hours, less than 15.5 hours, less than 15 hours, less than 14.5 hours, less than 14 hours or less than 13 hours. In one embodiment, the keratin and material, protease and non-sulphur containing surfactant may be admixed for less than 16 hours.
  • the keratin and material, protease and non-sulphur containing surfactant may be admixed for less than 13 hours
  • the keratin and material, protease and non-sulphur containing surfactant may be admixed for about 1 .5 to about 10 hours. In one embodiment, the keratin material, protease and non-sulphur containing surfactant may be admixed until at least 50% by weight of the keratin material is degraded. Optionally, the keratin material, protease and non-sulphur containing surfactant may be admixed until at least 55% (suitably at least 60% or at least 70% or at least 80% or at least 90% or 100%) by weight of the keratin material is degraded.
  • Degraded or degradation of feather material by 100% may be defined by the complete detachment of vanes, barbs and after feather from the rachis and hollow shaft; and the fragmentation of the rachis and hallow shaft such that feather meal is produced in one single step.
  • the keratin material e.g. wet feathers
  • the keratin material may be added to a vessel (e.g. at ambient temperature) and heated (for example to 50-80°C) with the addition of a protease, a non-sulphur containing surfactant and optionally a chemical and/or a reducing agent (e.g. sulfite).
  • the vessel may be a closed reactor optionally with reduced airspace to control oxygen levels.
  • the keratin material and protease are reacted for a suitable time (e.g. for 30 to 48 hours).
  • the vessel may be rotated or the vessel contents may be admixed (e.g. using a propeller at 1 -200 rpm).
  • the mixing may cause some oxygen to be continually introduced into to the reaction liquid.
  • the airspace of the vessel may advantageously have lower level of oxygen (e.g. through the use of stream to expel air out of the reactor).
  • the resultant keratin material e.g. feather meal
  • such a process has the advantages of reducing energy associated with grinding the keratin material and the utilisation of particular high temperatures (e.g. 120°C) which can lead to the damage of certain amino acids.
  • the pH during the reaction is within the working range of the protease used. It is a matter of routine to a person of ordinary skill in the art to determine the optimal working range of the protease used and to add buffer to adjust the reaction solution to an appropriate pH.
  • the working pH range of the protease Protex 30L (available from DuPont Industrial Biosciences ApS) may be from about 5.5 to about 12.
  • the pH during the admixing step may be from about 5.5 to about 12.
  • the pH range may be from about 7 to about 1 1 , or from about 8 to about 10.
  • the pH is about pH 9.
  • the pH used is a pH at about the optimal pH for the protease used.
  • the pH may be +/- about 1 pH of the optimal pH of the protease used (e.g. a pH of about 8 to about 10 for Protex 30L).
  • the pH may be +/- about 0.5 pH of the optimal pH of the protease used.
  • the pH used is the optimal pH of the protease.
  • the temperature during the reaction is adjusted to be within the working range of the protease used. It is a matter of routine to a person of ordinary skill in the art to determine the optimal working range of the protease used and to carry out the reaction at a desired temperature.
  • the working range of the protease Protex 30L may be from about 30°C to about 80°C.
  • the temperature during the admixing step may be from about 30°C to about 80°C.
  • the temperature may be from about 40°C to about 80°C, or from about 50°C to about 80°C.
  • the temperature may be or from about 60°C to about 80°C.
  • the temperature is about 70°C.
  • the temperature used may be + and/or - 15°C; or + and/or - 10°C; or + and/or - 5°C; or + and/or - 4°C; or + and/or - 3°C; or + and/or - 2°C; or + and/or - 1 °C of the optimal temperature of the protease used.
  • the temperature used is about the optimal working temperature of the protease used.
  • the temperature used is + and/or - 10°C of the optimal temperature of the protease used.
  • the temperature used is + and/or - 5°C of the optimal temperature of the protease used.
  • more than one enzyme may be present in the admixing step.
  • the temperature, pH and other reaction conditions used may then be selected to be within the working ranges of the enzymes used.
  • the enzymes used e.g. more than one protease and/or other additional enzymes
  • the enzymes are selected which have overlapping working ranges.
  • the enzymes are selected to have compatible, preferably similar working ranges.
  • the feather prior to admixing the keratin material with the protease and/or non-sulphur containing surfactant the feather may be sterilised e.g. to reduce and/or prevent bacterial contamination.
  • This sterilization step may be carried out by any available means.
  • fumigation could be achieved by contacting the keratin material with formalin or ethylene oxide gas.
  • steam sterilisation could be achieved by steaming under pressure.
  • steam sterilisation may be preferable to aid subsequent enzymatic degradation of the keratin material.
  • the keratin material may be pre-treated with steam to expel air from the vessel, to heat the vessel to a temperature of 40 to 121 °C (preferably 50- 80°C) and/or to sterilize the keratin material.
  • protease and/or sulfite may be admixed with the keratin material before or after such steam treatment.
  • the keratin material is steam sterilised prior to the reaction step.
  • the steam sterilisation comprises a step of contacting the keratin to steam for a time and at a temperature sufficient to facilitate the subsequent enzymatic hydrolysis thereof, even if this steam treatment step does not accomplish a complete sterilization of the keratin material.
  • the steam sterilisation may comprise contacting keratin material to steam under pressure, in an enclosed chamber, at 120 to 125 °C for at least 2 minutes, or at least 5 minutes, or at least 10 minutes, or at least 15 minutes, or at least 20 minutes.
  • the time and temperature of steam treatment may be less than those employed in commercial steam hydrolysis processes, which employ treatment times of 35 minutes or more at steam pressures of about 35 p.s.i. or more.
  • the methods of the present invention may comprise a chemical hydrolysis step which may occur prior to, during and/or after the reaction step with protease and/or non-sulphur-containing surfactant.
  • the methods of the present invention may comprise a chemical hydrolysis step which may occur prior to and/or during the reaction step with protease and/or non-sulphur-containing surfactant.
  • the methods of the present invention may comprise a chemical hydrolysis step which may occur after the reaction step with protease and/or non-sulphur-containing surfactant.
  • the acid or alkali used in the chemical hydrolysis may provide the means for pH adjustment to the optimal working conditions of the protease.
  • chemical hydrolysis may occur after the reaction step with a protease.
  • the process of the present invention may be carried out as a batch, fed-batch or continuous process.
  • the process of the present invention may be carried out in a batch process.
  • a batch process is more easily adapted for controlling oxygen levels.
  • the feather hydrolysate produced by the method of the present invention may be in the form of a precipitate.
  • particulate matter greater than 1 .0 cm (suitably greater than 0.1 cm) is recycled for pre-treatment or hydrolysis.
  • the feather hydrolysate produced by the method of the present invention may be in the form of a solution.
  • the method and uses of the present invention utilise a non-sulphur containing surfactant.
  • the term "surfactant” as used herein refers to a substance which reduces the surface tension of a liquid in which it is dissolved.
  • the surfactant may reduce the surface tension of water.
  • the surfactant may preferably act as a detergent, wetting agent, emulsifier or dispersant.
  • the surfactant may be amphiphilic (i.e. may contain both hydrophobic and hydrophilic groups.
  • the "surfactant” may be an "emulsifier".
  • emulsifier refers to substances which stabilise an emulsion by increasing its kinetic stability.
  • the surfactant used is not toxic to animals and/or humans.
  • the surfactant is selected from the group consisting of: sodium decanoate; Triton X-100; Tween 20; Tween 80; lecithin; polyoxyethylene stearate; polyoxyethylene sorbitan monolaurate; polyoxyethylene sorbitan monooleate; polyoxyethylene sorbitan monopalmitate; polyoxyethylene sorbitan monostearate; polyoxyethylene sorbitan tristearate; ammonium phosphatides; sodium, potassium or calcium salts of fatty acids; magnesium salts of fatty acids; acetic acid esters of mono- and diglycerides of fatty acids; lactic acid esters of mono- and diglycerides of fatty acids; citric acid esters of mono- and diglycerides of fatty acids; mono- and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids; sucrose esters
  • the surfactant is selected from the group consisting of: sodium decanoate; Triton X-100; Tween 20 and Tween 80.
  • the surfactant is sodium decanoate.
  • the surfactant is an emulsifier selected from the group consisting of: sodium decanoate; Triton X-100; Tween 20; Tween 80; lecithin; polyoxyethylene stearate; polyoxyethylene sorbitan monolaurate; polyoxyethylene sorbitan monooleate; polyoxyethylene sorbitan monopalmitate; polyoxyethylene sorbitan monostearate; polyoxyethylene sorbitan tristearate; ammonium phosphatides; sodium, potassium or calcium salts of fatty acids; magnesium salts of fatty acids; acetic acid esters of mono- and diglycerides of fatty acids; lactic acid esters of mono- and diglycerides of fatty acids; citric acid esters of mono- and diglycerides of fatty acids; mono- and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids; sucrose esters of fatty acids; sucroglycerides; polyglycerol est
  • surfactants are emulsifiers that are currently used in the food industry and are generally recognised as safe for use in food.
  • only one surfactant is used in combination with a protease in the methods and uses of the present invention.
  • any combinations of two or more surfactants are used. For example any combination of 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 surfactants may be used.
  • the optimal amount of surfactant to be used can be readily determined by a person of ordinary skill in the art.
  • the amount of surfactant used may be in the range of about 0.01 % w/v to about 1 % w/v.
  • the amount of surfactant may be in the range of about 0.05 - 0.9 %w/v.
  • the amount of surfactant used may be greater than or equal to 0.01 % w/v keratin material.
  • the amount of surfactant used may be greater than or equal to 0.02% w/v; or 0.05% w/v or 0.1 % w/v keratin material .
  • the amount of surfactant used may be less than or equal to 1 % w/v keratin material.
  • the amount of surfactant used may be less than or equal to 0.9% w/v; or 0.8% w/v or 0.5% w/v keratin material.
  • the amount of surfactant used may be in the range of about 0.1 g/Kg to about keratin material 10 g/Kg keratin material (e.g. feathers).
  • the amount of surfactant used may be in the range of about 0.5 g/Kg to about keratin material 5 g/Kg keratin material (e.g. feathers).
  • the amount of surfactant used may be greater than or equal to 0.1 g/Kg keratin material.
  • the amount of surfactant used may be greater than or equal to 0.5 g/Kg; or 1 g/Kg; or 2 g/Kg keratin material.
  • the amount of surfactant used may be less than or equal to 1 0 g/Kg keratin material.
  • the amount of surfactant used may be less than or equal to 8 g/Kg; or 5 g/Kg or 3 g/Kg keratin material.
  • the ratio of surfactant to keratin material may be in the range of about 1 :100 to about 1 :10,000.
  • the ratio of surfactant to keratin material may be in the range of about 1 :500 to about 1 :5,000.
  • the ratio of surfactant to keratin material may be greater than 1 :10,000.
  • the ratio of surfactant to keratin material may be less than 1 :100.
  • the surfactant is a non-sulphur containing surfactant.
  • a surfactant may work by opening up the hydrophobic keratin material in the solution thereby allowing the enzyme better access to the structure to carry out the hydrolysis.
  • the surfactant may help to remove hydrolyzed protein from the surface of the feather to solution so that the underlying surface of the feather is exposed to proteolysis.
  • a non-sulphur containing surfactant may be a surfactant for use in the methods and uses of the present invention if in a process for degrading a keratin material (e.g. feathers) there is an increase in the amount of soluble protein present in solution at the end of the process compared to the amount of soluble protein present in solution for a control method in which the non-sulphur containing surfactant was not used.
  • the increase in soluble protein may be measured by an increase in absorbance at 215-280 nm.
  • Keratin is a fibrous structural protein found in feather, hair, fur, hooves, nails, wool, claws and scales. Keratins can be divided into two separate groups a-keratins and ⁇ - keratins. The ⁇ -keratins are generally harder than a-keratins as they contain more cysteine linkages.
  • the keratin material for use in the methods and uses of the present invention can be any substance which comprises keratin.
  • the keratin material may comprise feathers, hair, fur, hooves, nails and wool.
  • the keratin material comprises ⁇ -keratin.
  • ⁇ -keratins may be found in nails and claws of reptile, shells of Testudines and in the feathers beaks and claws of birds and porcupines.
  • the keratin material may be feathers, preferably poultry feathers, preferably chicken feathers.
  • the keratin material comprises a-keratin.
  • a-keratins may be found in the hair (including wool), horns, nails, claws and hooves of mammals.
  • the keratin material may be hair, horns or hooves.
  • the keratin material comprises feathers, hair, horns, hooves or wool.
  • the keratin material may be feathers, hair, horns, hooves or wool.
  • At least 5 g of keratin material is used in the processes and uses of the present invention.
  • at least 50g, preferably at least 100g, preferably at least 500g keratin material is used in the processes and uses of the present invention.
  • At least 1 kg f keratin material is used, preferably. at least 2 kg, or at least 10kg, or at least 20kg, or at least 30kg keratin material is used.
  • protease as used herein is synonymous with peptidase or proteinase.
  • the protease for use in the present invention may be a subtilisin (E.C. 3.4.21 .62) or a bacillolysin (E.C. 3.4.24.28) or an alkaline serine protease (E.C. 3.4.21 .x) or a keratinase (E.C. 3.4.x.x).
  • a protease for use in the present invention may be an Protease endopeptidase K (EC 3.4.2.1 .64), an endopeptidase Arg-C, an endoprotease Gluc-C (EC 3.4.21 .19), an enterokinase (EC 3.4.21 .9), a collagenase (EC 3.4.24.3), a thermolysin (EC 3.4.24.27), a trypsin (EC 3.4.21 .4), a chymotrypsin (EC 3.4.21 .1 ), a pepsin (EC 3.4.23.1 ), an aspergillopepsin (EC 3.4.23.18), a sedolisin (EC 3.4.21 .100), or a dipeptidyl peptidase (EC 3.4.14.1 ).
  • Protease endopeptidase K EC 3.4.2.1 .64
  • an endopeptidase Arg-C an endoprotease
  • the protease in accordance with the present invention is a subtilisin, a serine protease, a metalloprotease, an acid protease, a neutral protease or a keratinase.
  • Suitable proteases include those of animal, vegetable or microbial origin. Chemically modified or protein engineered mutants are also suitable.
  • the protease may be a serine protease or a metalloprotease, e.g., an alkaline microbial protease or a trypsin-like protease.
  • alkaline proteases are subtilisins, especially those derived from Bacillus sp., e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309 (see, e.g., U.S. Patent No. 6,287,841 ), subtilisin 147, and subtilisin 168 (see, e.g., WO 89/06279).
  • trypsin-like proteases are trypsin (e.g., of porcine or bovine origin), and Fusarium proteases (see, e.g., WO 89/06270 and WO 94/25583).
  • useful proteases also include but are not limited to the variants described in WO 92/19729 and WO 98/201 15. All of which are incorporated herein by reference.
  • wild type protease enzyme or wild type in accordance with the invention describe a protease enzyme with an amino acid sequence found in nature.
  • protease variant or “variant” in accordance with the invention describe a protease enzyme with an amino acid sequence derived from the amino acid sequence of a parent protease but differing by one or more amino acid substitutions, insertions, and/or deletions, which together are referred to as "mutations”. It is envisaged that a protease enzyme variant may also be a parent protease enzyme for further rounds of methods of preparing protease variants such as molecular evolution.
  • homologous polypeptide(s) refers to polypeptides, preferably protease enzymes (i.e. "homologous protease " or “homologous enzymes") with a sequence identity of more than 75% compared to a first polypeptides/proteases/enzymes amino acid sequence, preferably has at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence homology.
  • functional equivalent thereof means that the enzyme has to have about the same functional characteristics as that of the protease detailed herein.
  • modified form or “variant” means that the enzyme has been modified from its original form but retains the same enzymatic functional characteristics.
  • variant or modified form encompass protease enzymes with an amino acid sequence derived from the amino acid sequence of the parent/wild-type protease and having one or more amino acid substitutions, insertions, and/or deletions, which together are referred to as mutations. Modified forms or variants may display altered enzyme characteristics compared to the parent enzyme.
  • modified forms or variants have one or more of the following enhanced phenotypes: increased thermostability and/or; an increased proteolytic (for example pepsin) stability and/or; an increased specific activity and/or; broader substrate specificity and/or; an activity over a broader pH range.
  • the term "functional” or “effective” fragment means a fragment or portion of the protease that retains about the same enzymatic function or effect.
  • thermoostable relates to the ability of the enzyme to retain activity after exposure to elevated temperatures.
  • pH stable relates to the ability of the enzyme to retain activity over a wide range of pH's.
  • the protease may be comprised in one or more of the following commercially available products: Kannase,TM, NovoCarne TenderTM' and Novozym 37020, Novo-Pro DTM (all available from Novozymes); BioSorb-ACDPTM (Noor Creations, India); or AngelTM Acid Protease (Angel Yeast Co, Ltd., China).
  • the protease may be a protease from Bacillus (such as Bacillus subtilis, Bacillus amyloliquefaciens, B. alcalophilus and B. licheniformis), Trichoderma, Nocardiopsis, Serratia or Aspergillus.
  • the protease is from Bacillus.
  • the protease may be from the species Bacillus subtilis, Bacillus amyloliquefaciens, B. alcalophilus, B. lentus and B. licheniformis.
  • the protease is from the species Bacillus subtilis. Amino acid sequences
  • the protease has the amino acid sequence ID No.1 . In one embodiment, the protease has the amino acid sequence ID No.2.
  • amino acid sequence is synonymous with the term “polypeptide” and/or the term “protein”. In some instances, the term “amino acid sequence” is synonymous with the term “peptide”. In some instances, the term “amino acid sequence” is synonymous with the term “enzyme”.
  • amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques.
  • the protein encompassed in the present invention may be used in conjunction with other proteins, particularly enzymes.
  • the present invention also covers a combination of proteins wherein the combination comprises the protease of the present invention and another enzyme, which may be another protease according to the present invention.
  • the amino acid sequence when relating to and when encompassed by the per se scope of the present invention is not a native enzyme.
  • the term "native enzyme” means an entire enzyme that is in its native environment and when it has been expressed by its native nucleotide sequence.
  • the present invention also encompasses the use of sequences having a degree of sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence encoding such a polypeptide (hereinafter referred to as a "homologous sequence(s)").
  • sequences having a degree of sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence encoding such a polypeptide hereinafter referred to as a "homologous sequence(s)"
  • the term “homologue” means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences.
  • the term “homology” can be equated with "identity”.
  • the homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.
  • an homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence.
  • the homologues will comprise the same active sites etc. as the subject amino acid sequence.
  • homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.
  • an homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to a nucleotide sequence encoding a polypeptide of the present invention (the subject sequence).
  • the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence.
  • homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.
  • Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.
  • Percentage homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.
  • a suitable computer program for carrying out such an alignment is the the Vector NTI (Invitrogen Corp.).
  • software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al 1999 Short Protocols in Molecular Biology, 4th Ed - Chapter 18), BLAST 2 (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1 ): 187-8 and tatiana@ncbi.nlm.nih.gov), FASTA (Altschul et al 1990 J. Mol. Biol. 403-410) and AlignX for example. At least BLAST, BLAST 2 and FASTA are available for offline and online searching (see Ausubel et al 1999, pages 7-58 to 7-60).
  • the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance.
  • a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance.
  • An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs.
  • Vector NTI programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the default values for the Vector NTI package.
  • percentage homologies may be calculated using the multiple alignment feature in Vector NTI (Invitrogen Corp.), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1 ), 237-244).
  • % homology preferably percentage sequence identity.
  • the software typically does this as part of the sequence comparison and generates a numerical result.
  • CLUSTAL may be used with the gap penalty and gap extension set as defined above.
  • the degree of identity with regard to a nucleotide sequence is determined over at least 20 contiguous nucleotides, preferably over at least 30 contiguous nucleotides, preferably over at least 40 contiguous nucleotides, preferably over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 100 contiguous nucleotides.
  • the degree of identity with regard to a nucleotide sequence may be determined over the whole sequence.
  • the present invention also encompasses the use of variants, homologues and derivatives of any amino acid sequence of a protein or of any nucleotide sequence encoding such a protein.
  • homologue means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences.
  • the term “homology” can be equated with "identity”.
  • a homologous sequence is taken to include an amino acid sequence which may be at least 75, 80, 85 or 90% identical, preferably at least 95, 96, 97, 98 or 99% identical to the subject sequence.
  • the homologues will comprise the same active sites etc. as the subject amino acid sequence.
  • homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.
  • an homologous sequence is taken to include a nucleotide sequence which may be at least 75, 80, 85 or 90% identical, preferably at least 95, 96, 97, 98 or 99% identical to a nucleotide sequence encoding an enzyme of the present invention (the subject sequence).
  • the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence.
  • homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.
  • Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate percentage homology between two or more sequences.
  • Percentage homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.
  • BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program.
  • a new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1 ): 187-8 and tatiana@ncbi.nlm.nih.gov).
  • the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance.
  • An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs.
  • GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.
  • percentage homologies may be calculated using the multiple alignment feature in DNASISTM (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1 ), 237-244).
  • sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance.
  • Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained.
  • negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine. Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other: ALIPHATIC Non-polar G A P
  • the present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc.
  • Non-homologous substitution may also occur i.e.
  • Z ornithine
  • B diaminobutyric acid ornithine
  • O norleucine ornithine
  • pyriylalanine thienylalanine
  • naphthylalanine phenylglycine
  • Replacements may also be made by unnatural amino acids include; alpha* and alpha-disubstituted* amino acids, N-alkyl amino acids*, lactic acid*, halide derivatives of natural amino acids such as trifluorotyrosine*, p-CI-phenylalanine*, p-Br- phenylalanine*, p-l-phenylalanine*, L-allyl-glycine*, ⁇ -alanine*, L-a-amino butyric acid*, L-y-amino butyric acid*, L-a-amino isobutyric acid*, L-s-amino caproic acid* 7- amino heptanoic acid*, L-methionine sulfone , L-norleucine*, L-norvaline*, p-nitro-L- phenylalanine*, L-hydroxyproline # , L-thioproline*, methyl derivatives of phen
  • Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or ⁇ -alanine residues.
  • alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or ⁇ -alanine residues.
  • a further form of variation involves the presence of one or more amino acid residues in peptoid form, will be well understood by those skilled in the art.
  • the peptoid form is used to refer to variant amino acid residues wherein the a-carbon substituent group is on the residue's nitrogen atom rather than the a-carbon.
  • Processes for preparing peptides in the peptoid form are known in the art, for example Simon RJ et ai, PNAS (1992) 89(20), 9367-9371 and Horwell DC, Trends Biotechnol. (1995) 13(4), 132-134.
  • any of the protease sequences according to the present invention is in an isolated form.
  • isolated means that the protease sequence is at least substantially free from at least one other component with which the protease sequence is naturally associated in nature and as found in nature.
  • the protease sequence of the present invention may be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. Thus, for example it may be substantially free of one or more potentially contaminating polypeptides and/or nucleic acid molecules.
  • the protease sequence according to the present invention is in a purified form.
  • purified means that the a given component is present at a high level.
  • the component is desirably the predominant component present in a composition. Preferably, it is present at a level of at least about 90%, or at least about 95% or at least about 98%, said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration.
  • the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Books 1 -3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; Current Protocols in Molecular Biology, ch. 9, 1 3, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A.
  • the protease is encoded by the nucleic acid sequence ID No.3.
  • the protease is encoded by the nucleic acid sequence ID No.4.
  • nucleotide sequence refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof).
  • the nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or anti-sense strand.
  • nucleotide sequence in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA sequence coding for the present invention.
  • the nucleotide sequence when relating to and when encompassed by the per se scope of the present invention does not include the native nucleotide sequence according to the present invention when in its natural environment and when it is linked to its naturally associated sequence(s) that is/are also in its/their natural environment.
  • the term "non-native nucleotide sequence" means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment.
  • amino acid sequence encompassed by scope the present invention can be isolated and/or purified post expression of a nucleotide sequence in its native organism.
  • amino acid sequence encompassed by scope of the present invention may be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism.
  • the nucleotide sequence encompassed by the scope of the present invention is prepared using recombinant DNA techniques (i.e. recombinant DNA).
  • the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH et al., (1980) Nuc Acids Res Symp Ser 215-23 and Horn T et al., (1980) Nuc Acids Res Symp Ser 225-232).
  • a nucleotide sequence encoding either a protein which has the specific properties as defined herein or a protein which is suitable for modification may be identified and/or isolated and/or purified from any cell or organism producing said protein.
  • Various methods are well known within the art for the identification and/or isolation and/or purification of nucleotide sequences. By way of example, PCR amplification techniques to prepare more of a sequence may be used once a suitable sequence has been identified and/or isolated and/or purified.
  • a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the enzyme. If the amino acid sequence of the enzyme is known, labelled oligonucleotide probes may be synthesised and used to identify enzyme-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known enzyme gene could be used to identify enzyme-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used.
  • enzyme-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming enzyme- negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar plates containing a substrate for enzyme (i.e. maltose), thereby allowing clones expressing the enzyme to be identified.
  • an expression vector such as a plasmid
  • transforming enzyme- negative bacteria with the resulting genomic DNA library
  • a substrate for enzyme i.e. maltose
  • the nucleotide sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage S.L. et ai, (1981 ) Tetrahedron Letters 22, p 1859- 1869, or the method described by Matthes et ai, (1984) EMBO J. 3, p 801 -805.
  • the phosphoroamidite method oligonucleotides are synthesised, e.g. in an automatic DNA synthesiser, purified, annealed, ligated and cloned in appropriate vectors.
  • the nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence.
  • the DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or in Saiki R K et al., ⁇ Science (1988) 239, pp 487-491 ).
  • the nucleotide sequences for use in the present invention may include within them synthetic or modified nucleotides.
  • a number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule.
  • the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of nucleotide sequences of the present invention.
  • the present invention also encompasses the use of nucleotide sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other organisms etc.
  • Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations.
  • other homologues may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein.
  • sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences in the attached sequence listings under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the invention.
  • Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention.
  • conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used.
  • the primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.
  • such polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.
  • Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or nonradioactive labels, or the polynucleotides may be cloned into vectors.
  • a primer e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or nonradioactive labels, or the polynucleotides may be cloned into vectors.
  • primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.
  • Polynucleotides such as DNA polynucleotides and probes according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.
  • primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.
  • Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques.
  • the primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.
  • the present invention also encompasses sequences that are complementary to the nucleic acid sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary thereto.
  • hybridisation shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction (PCR) technologies.
  • the present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the sequences presented herein, or any derivative, fragment or derivative thereof.
  • variant also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein.
  • the present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein).
  • the present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein). Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridising to the nucleotide sequences presented herein under conditions of intermediate to maximal stringency. In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under stringent conditions (e.g. 50°C and 0.2xSSC).
  • stringent conditions e.g. 50°C and 0.2xSSC
  • the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention, or the complement thereof, under high stringent conditions (e.g. 65°C and O.l xSSC).
  • high stringent conditions e.g. 65°C and O.l xSSC.
  • Molecular evolution As a non-limiting example, it is possible to produce numerous site directed or random mutations into a nucleotide sequence, either in vivo or in vitro, and to subsequently screen for improved functionality of the encoded polypeptide by various means.
  • mutations or natural variants of a polynucleotide sequence can be recombined with either the wildtype or other mutations or natural variants to produce new variants.
  • Such new variants can also be screened for improved functionality of the encoded polypeptide.
  • the production of new preferred variants can be achieved by various methods well established in the art, for example the Error Threshold Mutagenesis (WO 92/18645), oligonucleotide mediated random mutagenesis (US 5,723, 323), DNA shuffling (US 5,605,793), exo-mediated gene assembly WO00/58517.
  • Mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.
  • sequence for use in the present invention is a recombinant sequence - i.e. a sequence that has been prepared using recombinant DNA techniques.
  • sequence for use in the present invention is a synthetic sequence - i.e. a sequence that has been prepared by in vitro chemical or enzymatic synthesis. It includes, but is not limited to, sequences made with optimal codon usage for host organisms - such as the methylotrophic yeasts Pichia and Hansenula.
  • the keratin material comprises (or consists of) feathers and the protease is used in range of about 1 g/kg of keratin material to about 10g/kg keratin material.
  • the keratin material comprises (or consists of) wool, horns, hooves or admixtures thereof and the protease is used in range of about 1 g/kg of keratin material to about 50g/kg keratin material.
  • one protease unit is the amount of enzyme that liberates from the substrate (0.6% casein solution) one microgram of phenolic compound (expressed as tyrosine equivalents) in one minute at pH 7.5 (40mM Na 2 PO 4 / lactic acid buffer) and 40°C. This may be referred to as the assay for determining 1 PU.
  • the enzyme suitably as a subtilisin (E.C. 3.4.21 .62) or a bacillolysin (E.C. 3.4.24.28) or an alkaline serine protease (E.C. 3.4.21 .x) or a keratinase (E.C.
  • the protease is an alkaliphile and optimally hydrolyses at a pH between about pH 7 to about pH 12.
  • the protease may optimally hydrolyse at a pH between about pH 8 to about pH 1 1 .
  • the protease may optimally hydrolyse at a pH between about pH 8 to about pH 10.
  • the protease may optimally hydrolyse at a pH of about 9.
  • the protease is an acidophile and optimally hydrolyses at a pH between about pH 1 to about pH 7.
  • the protease may optimally hydrolyse at a pH between about pH 3 to about pH 6.
  • the protease may optimally hydrolyse at a pH between about pH 4 to about pH 5.
  • the protease is a neutrophile and optimally hydrolyses at a pH between about pH 6 to about pH 8.
  • the protease may optimally hydrolyse at a pH of about 7.
  • the protease may hydrolyse optimally at a temperature between about 30°C to about 98°C.
  • the protease may hydrolyse optimally at a temperature between about 40°C to about 80°C.
  • the protease may hydrolyse optimally at a temperature between about 50°C to about 80°C.
  • the protease may hydrolyse optimally at a temperature between about 60°C to about 80°C.
  • the keratin material, protease and non-sulphur containing surfactant may optionally be admixed (simultaneously or sequentially) with one or more further components.
  • further components include reducing agents, additional enzymes, chemicals, metal ions in the form of a salt, carriers, excipients, diluents, antimicrobials, fats, peptides and minerals.
  • one or more further components may be selected from the group consisting of: reducing agents, additional enzymes, antimicrobials, metal ions in the form of a salt, carriers, excipients, diluents, fats, peptides, minerals and combinations thereof
  • one or more additional enzyme(s) are added.
  • Said one or more additional enzymes may be selected from the group consisting of esterases, lipases, cutinases, protein-disulfide reductases (EC 1 .8.x.x), metal loproteases, aspartic acid proteases, cysteine proteases, exopeptidases, endoproteases, acyltransferases, perhydrolases, oxidases (e.g. hexose oxidases and maltose oxidoreductases), and proteases.
  • one or more one or more metal ions may be used in the form of a salt.
  • the metal ion may be one of the group consisting of Cu, Mg, Mn, Co, Zn, Fe and Ca.
  • the salt may be a chloride.
  • an antimicrobial is added as a further component.
  • sulphite or its salts are added as an antimicrobial.
  • the method and/or uses of the present invention further comprise the use of a reducing agent.
  • reducing agent refers to an element or compound in a reduction-oxidation (redox) reaction that donates an electron to another species.
  • redox reduction-oxidation
  • a reducing agent may stimulate keratin degradation by a protease. Without wishing to be bound by theory it is thought that reducing agents may breakdown disulphide bonds present in keratin, opening up the structure to aid hydrolysis by a protease.
  • a substance "stimulates" keratin degradation if it increases the speed by which a desired level of keratin degradation is reached and/or if it increases the amount of digestible protein and/or amount of amino acids available after a set time (e.g. 8 hours).
  • a reducing agent may be added prior to and/or during the step of reacting keratin material with a protease and a non-sulphur containing surfactant.
  • only one reducing agent is used in combination with a protease in the methods and uses of the present invention.
  • any combination of two or more reducing agents are used.
  • any combination of 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 surfactants may be used.
  • one or more reducing agent(s) may be selected from the group consisting of: salts of sulphite (e.g. Na2SO3 and NaHSOs), bisulfite, dithionite metabisulfite DTT, ⁇ -mercaptoethanol and sulphide.
  • salts of sulphite e.g. Na2SO3 and NaHSOs
  • bisulfite bisulfite
  • dithionite metabisulfite DTT dithionite metabisulfite
  • ⁇ -mercaptoethanol ⁇ -mercaptoethanol
  • the reducing agent may be sodium sulphite or sodium bisulphite.
  • one or more reducing agents may be added in the methods and uses of the present invention, the present inventors have surprisingly found that the use of a non- sulphur containing surfactant can reduce the amount of reducing agent used to achieve a desired degree of keratin degradation.
  • the reducing agent may be continuously added during the reaction of the keratin material with a protease and a non-sulphur containing surfactant.
  • continuous addition of a reducing agent during the reaction or a series of additions of the reducing agent (e.g. multiple dosing) during the reaction may result in improved enzymatic hydrolysis.
  • the reducing agent may be oxidised during the reaction leading to a depletion of reducing agent to break down the disulphide bonds in the keratin material. Therefore, multiple dosing or continuous addition of the reducing agent may allow a more linear reaction of keratin hydrolysis during the enzymatic reaction. Furthermore, multiple dosing and/or continuous addition of the reducing agent may allow more control over the levels of the reducing agent present at the end of the reaction. This may provide safety advantages as the process can be controlled to ensure lower amounts of the reducing agent in final product.
  • the reducing agent added may be continuous added or may be added in multiple doses (such as 2 or more times, or 3 or more times, or 4 or more times, or 5 or more times or 10 or more times).
  • oxygen levels may be controlled during the step of admixing the keratin material with a protease and a non-sulphur containing surfactant.
  • At least the step of admixing a keratin material with a protease and an emulsifier occurs under controlled oxygen levels.
  • This may be particularly advantageous when a reducing agent is added as a further component.
  • a reducing agent is added as a further component.
  • under controlled oxygen levels it is meant that that the reaction does not have unlimited access to oxygen (such as in an open system).
  • Various means of controlling oxygen levels are known in the art. For example, use of a closed system (e.g. a sealed vessel or reactor) results in a controlled level of oxygen present in the headspace above the reaction solution.
  • means of reducing the level of available oxygen can be employed such as heating the reaction medium, steam flushing, vacuum pumping and/or the addition of nitrogen (e.g. nitrogen bubbling).
  • At least the step of reacting a keratin material with a protease and a reducing agent may occur in a closed system (e.g. in a sealed vessel or reactor).
  • the level of oxygen is controlled such that the oxygen level in the air space of the reactor is less than 50% of the air, preferably less than 30% of the air, preferably less 5% of air in the reactor.
  • the enzymatic hydrolysis of keratin is combined with chemical hydrolysis.
  • the method of hydrolysing or degrading keratin using a protease and a non-sulphur containing surfactant can result in a reduction of the time and/or amount of chemicals needed using convention chemical hydrolysis methods.
  • the present inventors have surprisingly found that the combination of enzymatic and chemical hydrolysis of keratin can result in a quick and efficient process for keratin degradation.
  • the chemical hydrolysis step occurs prior to, during and/or after the reaction step with the protease and non-sulphur containing surfactant.
  • the chemical reaction may occur prior to and/or during step the enzymatic reaction and the chemical oxidant adjusts the pH to a desirable working pH of the protease.
  • the pH used for the chemical reaction is a pH under which the protease works.
  • the protease used is an alkaliphile and the chemical oxidant is an alkali.
  • the protease used is an acidophile and the chemical oxidant is an acid.
  • a chemical such as an acid, an akali or oxidant
  • a chemical oxidant may be used to chemically hydrolyse keratin.
  • chemical oxidants work by oxidising the disulphide bridges present in keratin which may result in the solubilisation of the keratin.
  • the use of a chemical oxidant may also increase the solubility of the keratin hydrolysate which may provide ease of application to e.g. feed.
  • solubility refers to the ability of hydrolysed keratin to dissolve in a solvent (e.g. in water).
  • the solubility of the keratin hydrolysate can be measured by determining the amount of nitrogen in the supernatant following centrifugation of the reaction mixture.
  • chemical oxidant refers to a substance that removes electrons from another reactant in a redox chemical reaction. Chemical oxidants are also referred to as oxidising agents or oxidants.
  • Examples of chemical oxidants which can hydrolyse keratin include sodium chlorite, HCI, acetic acid, hydroxyacetic acid, NaOH, peracids, HOCI, HOBr, NaCIO 2 , CIO 2 , H 2 O 2 , ammonium hydroxide, sodium hydroxide, and calcium hydroxide.
  • a peracid also known as a peroxy acid or peroxyacid
  • peracid is an acid which contains an acidic -OOH group.
  • the two main classes of peracids are those derived from conventional mineral acids, especially sulfuric acid, and the organic derivatives of carboxylic acids. Generally peracids are known to be strong oxidisers.
  • the peracid may be peracetic acid or performic acid.
  • the chemical may be added to the reaction medium or the chemical may be generated in the reaction medium.
  • peracetic acid may be generated in reaction medium. This can be achieved by the treatment of acetic acid with hydrogen peroxide using sulfuric acid as the catalyst: H2O2 + CH3CO2H + H 2 O. Hydrogen peroxide can be generated enzymatically by for example glucose oxidase and hexose oxidase. Peracetic acid can also be generated by the reaction of triacetin with H2O2 catalyzed by perhydrolase or aryl esterase.
  • the chemical may be generated in the reaction medium.
  • the keratin material and chemical are admixed until a desired degree of degradation of the keratin material has occurred (e.g. until the digestibility of keratin material is increased, such as by enriching the concentration of digestible proteins and peptides therein).
  • a desired degree of degradation of the keratin material e.g. until the digestibility of keratin material is increased, such as by enriching the concentration of digestible proteins and peptides therein.
  • the optimal time period used will depend on a number of factors such as the temperature and pH used; the degree of cross-linking present in the keratin material to be degraded; and whether other components are used in the process.
  • keratin material refers to admixing the chemical with the resultant material following treatment of keratin material with a protease.
  • the keratin material which is admixed with the chemical may be partially hydrolysed or degraded.
  • the keratin material may be in the form of a precipitate.
  • the chemical is used at a concentration of less than 50 mM, Suitably, the chemical is used at a concentration of less than 40 mM, preferably less than 30mM, preferably less than 20mM. Suitably, the chemical may be used at a concentration of less than 10mM.
  • the chemical is used at a concentration of between about 0.1 mM to about 49 mM.
  • the chemical may be used at a concentration of between about 0.2 mM and about 40mM, preferably at concentration between about 0.5 and about 10mM.
  • the keratin material and chemical may be admixed for about 5 minutes to about 24 hours or from about 1 0 minutes to about 20 hours or from about 15 minutes to about 16 hours or from about 30 minutes to about 10 hours or from about 1 hour to about 8 hours or from about 3 to about 7 hours.
  • the keratin material and chemical may be admixed for about 30min to 48 hours.
  • the keratin material and chemical may be admixed for about 1 hour to about 8 hours.
  • the keratin material and the chemical may be admixed for at least 5 minutes or at least 10 minutes or at least 15 minutes or at least 20 minutes or at least 25 minutes or at least 30 minutes or at least 45 minutes or at least 1 hour or at least 1 .5 hours or at least 2 hours or at least 2.5 hours or at least 3 hours or at least 3.5 hours or at least 4 hours or at least 4.5 hours or at least 5 hours or at least 5.5 hours or at least 6 hours or at least 7 hours or at least 8 hours or at least 9 hours or at least 10 hours.
  • the keratin material and the chemical may be admixed for at least 1 hour.
  • the keratin material and the chemical may be admixed for less than 24 hours, or less than 20 hours, or less than 16 hours, or less than 12 hours or less than 10 hours, or less than 8 hours, or less than 6 hours or less than 4 hours, or less than 2 hours or less than 1 hour.
  • the keratin material and the chemical may be admixed for less than 10 hours.
  • the keratin material and the chemical oxidant may be admixed until at least 50% by weight of the keratin material is degraded.
  • at least 60%, or at least 70%, or at least 80%, or at least 90% or at least 95% or 100% by weight of the keratin material is degraded.
  • the pH during the reaction will depend on the chemical used. For example, NaOH works at alkaline pH and HCI at acid pH.
  • the temperature during the reaction may be adjusted to optimise chemical degradation of the keratin material.
  • a combination of chemical and enzymatic hydrolysis is not generally used in the commercial production of keratin hydrolysate or the commercial degradation of keratin. This is primarily due to the increased costs associated with this combination.
  • Kim et al. disclose that a combination of 24 h enzyme treatment and 2-hour chemical treatment were significantly more than double the costs of enzyme treatment or chemical treatment alone.
  • enzymatic and chemical hydrolysis may be combined in a way which significantly reduces the costs typically associated with the combined use of enzymatic and chemical hydrolysis.
  • chemical hydrolysis occurs, preferably the chemical hydrolysis step with a chemical occurs at a time point in the process which avoids additional costs associated with the adjustment of the pH for the enzymatic reaction.
  • the chemical is an alkali and the chemical reaction occurs prior to or simultaneously with the enzymatic reaction.
  • the protease is an acid, preferably the chemical is an acid and the chemical reaction occurs prior to or simultaneously with the enzymatic reaction.
  • the protease is an alkaliphile and the chemical is an acid, preferably, the enzymatic reaction occurs prior to the chemical reaction so that the chemical reaction brings down the pH.
  • the protease is an acidophile and the chemical is an alkali, preferably, the enzymatic reaction occurs prior to the chemical reaction so that the chemical reaction brings up the pH. In this way, additional costs associated with raising or lowering the pH to optimal conditions for the protease are avoided.
  • the reaction conditions used are adapted to the working ranges of the protease used.
  • the chemical used for the chemical hydrolysis also adjusts the pH to the optimal working conditions of the protease, thereby advantageously providing the benefit of combined chemical and enzymatic reactions whilst minimising or avoiding additional costs associated with combining a chemical hydrolysis step with an enzymatic hydrolysis.
  • the protease Protex 30L works under high alkaline conditions.
  • this protease may be combined with an alkali known to chemically hydrolyse keratin such as NaOH.
  • the alkali then works to adjust the pH to the working range of the protease whilst also degrading keratin itself.
  • chemical and enzymatic hydrolysis can be combined in a cost-effective way.
  • a protease which works under acidic conditions can be combined with an acid known to degrade keratin such as HCI in a similar way.
  • the methods of the present invention may use an acidophilic protease.
  • the methods of the present invention may comprise a chemical hydrolysis step prior to and/or during the reaction with protease, wherein the chemical hydrolysis step uses an acid.
  • the methods of the present invention may use an alkaliphilic protease.
  • the methods of the present invention may comprise a chemical hydrolysis step prior to and/or during the reaction with protease, wherein the chemical hydrolysis step uses an alkali.
  • keratin hydrolysate may be produced which advantageously has an enhanced protein digestibility and/or increased source of amino acids compared to the use of either enzymatic or chemical hydrolysis alone.
  • protein digestibility may be measured by measuring Kjeldahl N content (e.g. in a N autoanalyzer) of the supernatant, following centrifugation of the reaction mixture.
  • “increased source of amino acids” refers to an increase in in vitro amino acid digestibility which may be measured in accordance with Kim et al. (Poultry Science, 2002, 85:95-98) using the following equation: amino acid content (g/100g reaction precipitate) of treatment
  • the chemical hydrolysis step may occur after the reaction step with a protease. This may be advantageous in situations where the protease selected and the chemical oxidant selected does not work at overlapping pH.
  • a method for producing animal feed comprising admixing keratin hydrolysate produced by a method of the present invention with one or more animal feed constituents.
  • keratin hydrolysate produced in the accordance with a method of the present invention may provide a valuable source of protein and/or source of amino acids in animal feed.
  • keratin hydrolysate can provide a source of one or more of the following amino acids: methionine, cysteine, lysine, threonine, arginine, isoleucine, leucine, valine, histidine, phenylalanine, glycine, serine, proline, alanine, aspartic acid and glutamic acid.
  • the terms “animal feed” and “feedstuff' are used interchangeably herein.
  • animal feed constituents and “feed ingredients” are also used interchangeably.
  • Animal feed is typically produced in feed mills in which raw materials are first ground to a suitable particle size and then mixed with appropriate additives.
  • the animal feed may then be produced as a mash or pellets; the later typically involves a method by which the temperature is raised to a target level and then the feed is passed through a die to produce pellets of a particular size. The pellets are allowed to cool.
  • liquid additives such as fat and enzyme may be added.
  • Production of the animal may also involve an additional step that includes extrusion or expansion prior to pelleting - in particular by suitable techniques that may include at least the use of steam.
  • broiler chickens may be comprised of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:
  • a feedstuff laying hens may be comprises of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:
  • a feedstuff for turkeys may be comprises of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:
  • a feedstuff for piglets may be comprises of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:
  • a feedstuff for grower/finisher pigs may be comprises of one or more of the ingredients listed in the table below, for example in the percentages given in the table below:
  • Vegetable oil 0.5 By way of example only the diet specification for grower/finisher pigs may be as set out in the table below:
  • keratin hydrolysate can be used as a good and potentially cheap source of protein and/or amino acids required in these diets.
  • the keratin hydrolysate produced in accordance with the present invention may be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant or a nutritionally active ingredient.
  • animal feed means food suitable for animal consumption, such as for cows, pigs, lamb, sheep, goats, chickens, turkeys, ostriches, pheasants, deer, elk, reindeer, buffalo, bison, antelope, camels, kangaroos; horses, fish; cats, dogs, guinea pigs, rodents e.g. rats, mice, gerbils and chinchillas.
  • the keratin hydrolysate produced in accordance with the present invention may be added to the animal feed or a component in a manner known per se.
  • the feed may be a fodder, or a premix thereof, a compound feed, or a premix thereof.
  • keratin hydrolysate produced in accordance with the present invention may be admixed with, and/or applied onto, a compound feed, a compound feed component or to a premix of a compound feed or to a fodder, a fodder component, or a premix of a fodder.
  • fodder as used herein means any food which is provided to an animal (rather than the animal having to forage for it themselves). Fodder encompasses plants that have been cut.
  • fodder includes hay, straw, silage, compressed and pelleted feeds, oils and mixed rations, and also sprouted grains and legumes.
  • Fodder may be obtained from one or more of the plants selected from: alfalfa (lucerne), barley, birdsfoot trefoil, brassicas, Chau moellier, kale, rapeseed (canola), rutabaga (swede), turnip, clover, alsike clover, red clover, subterranean clover, white clover, grass, false oat grass, fescue, Bermuda grass, brome, heath grass, meadow grasses (from naturally mixed grassland swards, orchard grass, rye grass, Timothy- grass, corn (maize), millet, oats, sorghum, soybeans, trees (pollard tree shoots for tree-hay), wheat, and legumes.
  • alfalfa lucerne
  • barley birdsfoot trefoil
  • brassicas Chau moellier
  • kale kale
  • rapeseed canola
  • rutabaga rutabaga
  • compound feed means a commercial feed in the form of a meal, a pellet, nuts, cake or a crumble.
  • Compound feeds may be blended from various raw materials and additives. These blends are formulated according to the specific requirements of the target animal.
  • Compound feeds can be complete feeds that provide all the daily required nutrients, concentrates that provide a part of the ration (protein, energy) or supplements that only provide additional micronutrients, such as minerals and vitamins.
  • the main ingredients used in compound feed are the feed grains, which include corn, soybeans, sorghum, oats, and barley.
  • a premix as referred to herein may be a composition composed of microingredients such as vitamins, minerals, chemical preservatives, inhibitory substances, fermentation products, and other essential ingredients. Premixes are usually compositions suitable for blending into commercial rations.
  • one or more feed materials may be added selected from the group comprising a) cereals, such as small grains (e.g., wheat, barley, rye, oats and combinations thereof) and/or large grains such as maize or sorghum; b) by products from cereals, such as corn gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp; c) protein obtained from sources such as soya, sunflower, peanut, lupin, peas, fava beans, cotton, canola, fish meal, dried plasma protein, meat and bone meal, potato protein, whey, copra, sesame; d) oils and fats obtained from vegetable and animal sources; e) minerals and vitamins.
  • Animal feed produced by the method of the present invention may contain at least 30%, at least 40%, at least 50% or at
  • animal feed produced by a method of the present invention may comprise at least one high fibre feed material and/or at least one byproduct of the at least one high fibre feed material to provide a high fibre feedstuff.
  • high fibre feed materials include: wheat, barley, rye, oats, by products from cereals, such as corn gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp.
  • Some protein sources may also be regarded as high fibre: protein obtained from sources such as sunflower, lupin, fava beans and cotton.
  • the feed may be one or more of the following: a compound feed and premix, including pellets, nuts or (cattle) cake; a crop or crop residue: corn, soybeans, sorghum, oats, barley, corn stover, copra, straw, chaff, sugar beet waste; fish meal; freshly cut grass and other forage plants; meat and bone meal; molasses; oil cake and press cake; oligosaccharides; conserved forage plants: hay and silage; seaweed; seeds and grains, either whole or prepared by crushing, milling etc.; sprouted grains and legumes; yeast extract.
  • a compound feed and premix including pellets, nuts or (cattle) cake
  • a crop or crop residue corn, soybeans, sorghum, oats, barley, corn stover, copra, straw, chaff, sugar beet waste
  • fish meal freshly cut grass and other forage plants
  • meat and bone meal molasses
  • oil cake and press cake oligosaccharides
  • the term “applied” refers to the indirect or direct application of the keratin hydrolysate produced in accordance with the present invention to the product (e.g. the feed).
  • the application methods include, but are not limited to, treating the product in a material comprising the keratin hydrolysate, direct application by mixing the keratin hydrolysate with the product, spraying the keratin hydrolysate onto the product surface or dipping the product into a preparation of the keratin hydrolysate .
  • the keratin hydrolysate produced by a method of the present invention is preferably admixed with, or applied onto, the product (e.g. feedstuff).
  • the product e.g. feedstuff
  • the keratin hydrolysate may be included in the emulsion or raw ingredients of a feedstuff.
  • swine relates to non-ruminant omnivores such as pigs, hogs or boars.
  • swine feed includes about 50 percent carbohydrate, about 20 percent protein and about 5% fat.
  • An example of a high energy swine feed is based on corn which is often combined with feed supplements for example, protein, minerals, vitamins and amino acids such as lysine and tryptophan.
  • feed supplements for example, protein, minerals, vitamins and amino acids such as lysine and tryptophan.
  • swine feeds include animal protein products, marine products, milk products, grain products and plant protein products, all of which may further comprise natural flavourings, artificial flavourings, micro and macro minerals, animal fats, vegetable fats, vitamins, preservatives or medications such as antibiotics.
  • Poultry relates to fowl such as chickens, broilers, hens, roosters, capons, turkeys, ducks, game fowl, pullets or chicks.
  • Poultry feeds may be referred to as "complete” feeds because they contain all the protein, energy, vitamins, minerals, and other nutrients necessary for proper growth, egg production, and health of the birds.
  • poultry feeds may further comprise vitamins, minerals or medications such as coccidiostats (for example Monensin sodium, Lasalocid, Amprolium, Salinomycin, and Sulfaquinoxaline) and/or antibiotics (for example Penicillin, Bacitracin, Chlortetracycline, and Oxytetracycline).
  • coccidiostats for example Monensin sodium, Lasalocid, Amprolium, Salinomycin, and Sulfaquinoxaline
  • antibiotics for example Penicillin, Bacitracin, Chlortetracycline, and Oxytetracycline.
  • fertilizer feed such reference is meant to include “starter” feeds(post-hatching),”finisher", “grower” or “developer” feeds (from 6- 8 weeks of age until slaughter size reached) and “layer” feeds (fed during egg production).
  • the "animal feed” may be a pet food.
  • pet food as used herein means a food suitable for consumption by a domesticated animal such as a dog, cat, horse, pig, fish, bird, hamster, gerbil, guinea pig, rodent e.g. rat, mouse, rabbit and chinchilla
  • the keratin hydrolysate may be applied on, or in , the pet food itself and/or constituent(s) (e.g. ingredients) of the pet food.
  • the keratin hydrolysate may be applied on, or in, a palatant.
  • Examples of typical constituents found in dog and cat food include palatants, Whole Grain Corn, Soybean Mill Run, Chicken By-Product Meal, Powdered Cellulose, Corn Gluten Meal, Soybean Meal, Chicken Liver Flavor, Soybean Oil, Flaxseed, Caramel Color, Iodized Salt, L-Lysine, Choline Chloride, Potassium Chloride, vitamins (L- Ascorbyi-2- Polyphosphate (source of vitamin C), Vitamin E Supplement, Niacin, Thiamine Mononitrate, Vitamin A Supplement, Calcium Pantothenate, Biotin, Vitamin B12 Supplement, Pyridoxine Hydrochloride, Riboflavin, Folic Acid, Vitamin D3 Supplement), Vitamin E Supplement, minerals (e.g., Ferrous Sulfate, Zinc Oxide, Copper Sulfate, Manganous Oxide, Calcium lodate, Sodium Selenite), Taurine, L- Carnitine, Glucosamine, Mixed Tocopherols, Beta-Caroten
  • a pet food recipe suitable for addition of the keratin hydroiysate of the current invention may be based on the following main ingredients: maize meals (whole, meal, or ground), poultry edible offal meal, wheat bran, alfalfa meal, maize gluten, rice, linseed meal, rapeseed meal, soybean meal or bean meal.
  • this recipe also contains stabilizers, and is supplemented with various vitamins and antioxidants such as vitamin a, cholecalciferol, vitamin e, menadione, citric acid, pantothenic acid, folic acid, vitamin b12, vitamin b6, riboflavin (vitamin b2), vitamin b , niacin (vitamin b3), and preferably flavour enhancers such as glutamine, taurine, yeast extract, and salt.
  • said recipe may be supplemented with a reconstituted food ingredient such as beef meal, powdered beef bone, chicken fat, chicken liver (hydrolyzed), fish meal or fish powder (such as tuna powder).
  • the pet food may be a wet or dry pet food, which may be in the form of a moist pet food (e.g. comprising 18-35% moisture), semi-moist pet food (e.g. 14 to 18% moisture), dry pet food, pet food supplement or a pet treat.
  • a moist pet food e.g. comprising 18-35% moisture
  • semi-moist pet food e.g. 14 to 18% moisture
  • dry pet food e.g. 14 to 18% moisture
  • pet food supplement or a pet treat e.g. moist and semi-moist pet food
  • Some pet food forms are particularly susceptible to contamination due to the fact that the processing conditions for preparing the pet food are not sufficient to kill all microorganisms on, or in, the pet food.
  • the pet food may be in kibble form.
  • the pet food may be suitable for a dog or a cat.
  • the pet food prepared with said keratin hydroiysate of the current invention may be described as anallergeinc if it assists pets that usually experience adverse food reactions to the extent that the animals can be described as having food allergies or intolerances, and in the worst cases inflammatory bowel disease.
  • a typical anallergeinc pet food composition usually maintains the standard 20% protein composition, which can be in the form of keratin hydrolysate if the pepsin digestability is sufficiently high (ideally greater than 75%), and also contains such innocuous ingredients as corn starch, coconut oil, soybean oil or hydrolysed soy, natural flavours, potassium phosphate, powdered cellulose, calcium carbonate, sodium silico aluminate, chicory, L-tyrosine, fructooligosaccharides, fish oil, L-lysine, choline chloride, taurine, L-tryptophan, vitamins [DL-alpha tocopherol (source of vitamin E), inositol, niacin, L-ascorbyl-2-polyphosphate (source of vitamin C), D-calcium panthotenate, biotin, pyridoxine hydrochloride (vitamin B6), riboflavine (vitamin B2), thiamine mononitrate (vitamin B1 ),
  • the pet food may be fish food.
  • a fish food normally contains macro nutrients, trace elements and vitamins necessary to keep captive fish in good health .
  • Fish food may be in the form of a flake, pellet or tablet. Pelleted forms, some of which sink rapidly, are often used for larger fish or bottom feeding species. Some fish foods also contain additives, such as beta carotene or sex hormones, to artificially enhance the colour of ornamental fish.
  • the pet food may be a bird food.
  • Bird food includes food that is used both in birdfeeders and to feed pet birds. Typically bird food comprises of a variety of seeds, but may also encompass suet (beef or mutton fat).
  • the keratin hydrolysate may be incorporated within the pet food or on the surface of the pet food, such as, by spraying or precipitation thereon.
  • the keratin hydrolysate is formulated for use in pet food.
  • the keratin hydrolysate may comprise additional anti-contaminant agents such as phosphoric acid, propionic acid and propionates, sulfites, benzoic acid and benzoates, nitrites, nitrates and parabens.
  • the keratin hydroiysate may be added to a pet food or constituent thereof such that the keratin hydroiysate is present at about 0.1 % to about 0%, about 0.1 to about 5%, or about 0.1 to about 3% by weight of the pet food.
  • the anti- contaminant composition is present at about 0.1 , 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 .0, 1 .1 , 12., 1 .3, 1 .4, 1 .5, 1 .6, 1 .7, 1 .8, 1 .9, 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.5, 4.0, 4.5, or 5.0% by weight of the pet food where any of the stated values can form an upper or lower endpoint when appropriate.
  • the pet food may be a kibble.
  • An illustrative method of preparing a kibble comprises the following steps:
  • preconditioning by mixing wet and dry ingredients at elevated temperature to form a kibble dough
  • the keratin hydroiysate can be applied to the kibble at any stage in the process, such as at step a and/or d.
  • the keratin hydroiysate produced by the method of the present invention may be used in any suitable form - whether when alone or when present in a composition.
  • Said composition may include other nutrition-rich waste streams from slaughter houses such as blood or meat and bone meal, or it may be prepared in a composition with other animal feeds including but not limited to soybean meal, fish meal, fish oil, whey powder, whey filtrate, distillers grains, cottonseed meal, corn gluten meal, canola meal, and the like.
  • the dry powder or granules may be prepared by means known to those skilled in the art, such as, in top-spray fluid bed coater, in a buttom spray Wurster or by drum granulation (e.g. High sheer granulation), extrusion, pan coating or in a microingredients mixer.
  • the keratin hydrolysate may be provided as a spray-dried or freeze-dried powder.
  • An example of such a spray dried keratin hydrolysate is shown in example 5.
  • Such spray dried powders have the advantages of increased stability and handling compared to forms with a higher water content, but said powders are still able to be provided in solution or suspended form to young animals most in need of nutritional supplement.
  • the spray dried keratin hydorlysate is in a powder form especially suitable for feeding young pets and commercial livestock, including but not limited to cows, pigs, mink, dogs, cats, broiler chickens and turkeys.
  • the small particle size of the spray dried keratin hydrolysate also makes it particularly suitable for smaller creatures such as young fish (fry), and crustaceans such as shrimp and crabs.
  • the keratin hydrolysate is in a liquid formulation.
  • Such liquid consumption may contain one or more of the following: a buffer, salt, sorbitol and/or glycerol.
  • the keratin hydrolysate of the present invention may formulated with at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch, Na 2 SO 4 , Talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1 ,3-propane diol, glucose, parabens, sodium chloride, citrate, acetate, phosphate, calcium, metabisulfite, formate and mixtures thereof.
  • at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch, Na 2 SO 4 , Talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1 ,3-prop
  • the enzyme(s) used in the present invention may be in an isolated form.
  • isolated means that the enzyme is at least substantially free from at least one other component with which the enzyme is naturally associated in nature and as found in nature.
  • the enzyme of the present invention may be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. Thus, for example it may be substantially free of one or more potentially contaminating polypeptides and/or nucleic acid molecules.
  • the enzyme according to the present invention is in a purified form.
  • purified means that the enzyme is present at a high level.
  • the enzyme is desirably the predominant component present in a composition. Preferably, it is present at a level of at least about 90%, or at least about 95% or at least about 98%, said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration.
  • Sodium sulfite (Sigma S0505) and sodium bisulfite (E222)(24,397-3, Sigma-Aldrich) were purchased from Sigma (St Louis, USA), Grindsted® SSL P 55 VEG K-A (E481 , Sodium stearoyl lactate) and Panodan® 517 KOSHER (E472e diacetyltartaric acid esters of mono- and diglycerides), Protex 6L (127000 units/g) and Protex 30L (48208 units/g) were from Danisco A S (Brabrand, Denmark).
  • the reaction mixtures contained 9ml water, 1 ml tris-HCI (0.48M, pH8.5), one chicken feather, 150 microliter of Protex 30L and the reducing agent given in Table 1 .
  • the reactors of 13ml volume yellow cap tubes were screwed airtight with lock. The reaction was incubated at 50°C with shaking at 100 rpm overnight (13h). Table 1
  • the reaction mixtures contained 12ml water, 1 ml tris-HCI (0.48M, pH8.5), one chicken feather, 150 microliter of Protex 6L and the emulsifier and/or reducing agent as detailed in Table 2 below.
  • the reactors of 13ml volume yellow cap tubes were screwed airtight with lock. The reaction was incubated at 50°C with shaking at 100 rpm overnight (13h). The test-tube simulated a free-fall reactor as during the shaking the feather was moving freely in the tube.
  • Buffer Tris-HCI 50mM Buffer Tris-HCI (pH8.5) containing 0.005% Tween-80 (emulsifier Tween 80, Polysorbate 80, E433).
  • TNBS solution Picrylsulfonic Acid Sigma cat.#P5878
  • Keratin ICN Biochemical, cat. #9021 1 1 ) which was prepared from hooves and horns.
  • the keratin was prepared in 5mg/mL concentrations using the buffer. 1 .5mL substrate was liquated into wells of a 24-well Co-Star plate while the mixture was stirred. Plates were covered with heat-resistant plate sealers. Plates were pre- incubated at 37°C for about 20 minutes prior to enzyme addition.
  • Plates containing the substrate solution were pre-incubated for about 20 minutes using the desired temperature prior to enzyme addition.
  • the diluted Protex P was added and the reaction mixture was incubated at 37oC, 150 rpm for 2 hours.
  • TNBS solution prepared freshly
  • Reagent A1 ⁇ 2 Reagent A1 ⁇ 2
  • A60uL of this solution was aliquoted into a 96-well microtiter plate.
  • 10ul of the reaction mixture was added and mixed for 20 minutes in a plate shaker at room temperature, of Reagent B was added, mixed for 1 minute and the endpoint was read at A405nm.
  • Reagent A 1 ⁇ 2 (1 liter), 2.4g NaOH, 45.4g Na2B4O7.10H2O, Dissolved by heating.
  • Reagent B (2 liters), 70.4g NaH2PO4.H2O, 1 2g Na2SO3
  • Sodium decanoate (>98%), Triton X-100TM, Tween 20®, and sodium bisulfite were obtained from Sigma-Aldrich, Switzerland.
  • Panodan®, SSL®, and Protex® P were obtained from DuPont Nutrition Biosciences Denmark, Denmark. All other chemicals used were of analytic grade.
  • Feather hydrolysate samples prepared with and without Protex P were centrifuged (10 min, 10.000 x g) and two fractions separated.
  • the soluble fraction (the supernatant) contained soluble peptides
  • the pellet fraction (the precipitate) contained insoluble peptides.
  • the pellet fraction was dried in a freeze drier until constant weight, and weighed.
  • the percent of hydrolyzed feather was approximately 60% for the sample including Protex P and approximately 4% for the sample without Protex P, calculated as per equation 1 . Equation 1 .
  • X2 Dry matter mass (g) of pellet fraction
  • the supernatant from the Protex P hydrolyzed feathers was filtered through a 355 ⁇ screen.
  • a Buchi B-191 mini-spray dryer was first started up and run at stable conditions with ion exchanged water with parameters as table 3. Once parameters were stable chicken feather hydrolysate was loaded at a feed rate of 30%, and the resulting white powder product collected.
  • the powder had a very light white appearance with moisture content of approximately 3% as measured on an A&D ML- 50 moisture analyzer (105° C drying temperature). Table 3
  • the five non-sulphur containing surfactants increased the extent of feather hydrolysis by 16-62 % compared to the reaction without emulsifier present, see Table 3 below. These results clearly show the positive effect of adding a non-sulphur containing surfactant together with protease for the hydrolysis of feather, when compared to reaction without emulsifier present.
  • the non-sulphur containing surfactants promote the reaction by making the substrate more accessible for the protease e.g. by opening up the structure of the feather substrate.
  • the five emulsifiers in absence of protease showed the non-sulphur containing surfactants do not merely increase the solubility of certain proteins, see Fig. 6.
  • Control reaction with neither a non-sulphur containing surfactant nor a protease present. Relative comparisons based on one-way ANOVA generated means.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP13739699.0A 2012-07-20 2013-07-19 Method for the degradation of keratin and use of the keratin hydrolysate produced Withdrawn EP2874504A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1212934.2A GB201212934D0 (en) 2012-07-20 2012-07-20 Method
PCT/EP2013/065362 WO2014013080A1 (en) 2012-07-20 2013-07-19 Method for the degradation of keratin and use of the keratin hydrolysate produced

Publications (1)

Publication Number Publication Date
EP2874504A1 true EP2874504A1 (en) 2015-05-27

Family

ID=46881715

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13739699.0A Withdrawn EP2874504A1 (en) 2012-07-20 2013-07-19 Method for the degradation of keratin and use of the keratin hydrolysate produced

Country Status (11)

Country Link
US (1) US20150208694A1 (pt)
EP (1) EP2874504A1 (pt)
CN (1) CN104507329A (pt)
AU (1) AU2013291942A1 (pt)
BR (1) BR112015001227A2 (pt)
GB (1) GB201212934D0 (pt)
IN (1) IN2014DN10710A (pt)
MX (1) MX2015000748A (pt)
PH (1) PH12014502763A1 (pt)
RU (1) RU2015105743A (pt)
WO (1) WO2014013080A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109652093A (zh) * 2019-02-20 2019-04-19 福建三炬生物科技股份有限公司 一种土壤调理剂及其制备方法和应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913151T3 (es) * 2016-09-13 2022-05-31 Basf Se Hidrolizados de queratina de bajo peso molecular.
CN107118984B (zh) * 2017-05-09 2018-06-08 山东省农业科学院生物技术研究中心 一种角蛋白降解菌的发酵罐发酵工艺及其在生猪脱毛中的应用
US11540994B2 (en) * 2017-10-06 2023-01-03 Meat & Livestock Australia Ltd Removal of biological deposits
EP3723893B1 (en) * 2017-12-15 2023-07-05 Universidade Católica Portuguesa - UCP Method for extracting keratin
CN108841747B (zh) * 2018-06-25 2020-08-14 青岛农业大学 产蛋白酶的枯草芽孢杆菌及使用方法
EP3867394A1 (en) * 2018-10-17 2021-08-25 Bioextrax AB Process for production of keratin microfibers and protein hydrolysate from poultry feathers via microbial hydrolysis
FR3093275B1 (fr) * 2019-02-28 2023-04-14 Bretagne Chimie Fine Composition à hautes teneurs en acides aminés libres et utilisation en tant que matière première et aliment complet pour l’alimentation animale.
CN113307860A (zh) * 2021-06-11 2021-08-27 四川大学 基于生物酶解作用从制革回收牛毛中提取角蛋白的方法
CN114262676B (zh) * 2021-12-21 2024-01-26 江苏丘陵地区南京农业科学研究所 一种利用芽孢杆菌高效降解羽毛角蛋白产氨基酸的方法
CN116035115A (zh) * 2023-03-07 2023-05-02 上海福智宠物食品有限公司 一种羽毛粉的制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3527913A1 (de) * 1985-08-03 1987-02-12 Henkel Kgaa Alkalische protease, verfahren zur herstellung von hybridvektoren und genetisch transformierte mikroorganismen
US4908220A (en) * 1988-03-31 1990-03-13 North Carolina State University Feather-lysate, a hydrolyzed feather feed ingredient and animal feeds containing the same
US5543302A (en) * 1988-05-27 1996-08-06 Solvay Enzymes, Inc. Proteases of altered stability to autolytic degradation
DE19835055A1 (de) * 1998-08-04 2000-02-24 Wella Ag Verfahren zur Bestimmung des Zustandes von Haaren sowie hierfür geeignete Vorrichtungen und Mittel
DK1373296T3 (da) * 2001-03-23 2012-01-09 Procter & Gamble Proteiner, der frembringer et ændret immunogent respons, og fremgangsmåder til fremstilling og anvendelse deraf
JP2005120286A (ja) * 2003-10-17 2005-05-12 Little Scientist:Kk 羽毛ケラチン加水分解物またはその塩、及びこれらを含有する化粧料組成物、並びに羽毛ケラチン加水分解物またはその塩の製造方法
AR053634A1 (es) * 2005-06-24 2007-05-09 Novozymes As Lipasas para uso farmaceutico
JP2012524542A (ja) * 2009-04-24 2012-10-18 ダニスコ・ユーエス・インク 修飾されたプロ（ｐｒｏ）領域をもつプロテアーゼ
AR076311A1 (es) * 2009-07-31 2011-06-01 Danisco Us Inc Proteasas con regiones pre- pro modificadas
EP2776570B1 (en) * 2011-11-07 2019-08-28 Mars, Incorporated Food protein ingredient and methods for producing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014013080A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109652093A (zh) * 2019-02-20 2019-04-19 福建三炬生物科技股份有限公司 一种土壤调理剂及其制备方法和应用

Also Published As

Publication number Publication date
GB201212934D0 (en) 2012-09-05
CN104507329A (zh) 2015-04-08
BR112015001227A2 (pt) 2017-12-12
MX2015000748A (es) 2015-04-16
PH12014502763A1 (en) 2015-02-09
US20150208694A1 (en) 2015-07-30
AU2013291942A1 (en) 2015-01-22
RU2015105743A (ru) 2016-09-10
WO2014013080A1 (en) 2014-01-23
IN2014DN10710A (pt) 2015-09-04

Similar Documents

Publication Publication Date Title
AU2013291943B2 (en) Method for the degradation of keratin and use of the keratin hydrolysate produced
AU2017202708A1 (en) Method for the degradation of keratin and use of the keratin hydrolysate produced
US20150208694A1 (en) Method for the degradation of keratin and use of the keratin hydrolysate produced
AU2016288515B2 (en) Methods of improving animal performance
US20200245642A1 (en) Use of proline tolerant tripeptidyl peptidases in feed additive compositions
EP2421386A2 (en) Feed supplement
EP2879513A2 (en) Method
WO2016110523A1 (en) Process for the hydrolysis of keratin employing proteases
WO2012168473A2 (en) Fusion of bioactive molecules
CN105120681A (zh) 动物饲料酶
Kumar et al. Production of feather protein concentrate from feathers by in vitro enzymatic treatment, its biochemical characterization and antioxidant nature
CN112654256A (zh) 动物饲料组合物及其用途
EP4297583A1 (en) Method of improving carbohydrate digestibility by a carbohydratase in an animal feed by employing serine protease
WO2022179757A1 (en) Method of improving carbohydrate digestibility by a carbohydratase in an animal feed by employing serine protease
Class et al. Patent application title: FOOD ADDITIVE COMPRISING AN AMIDASE FOR DETOXIFYING OCHRATOXIN Inventors: Shukun Yu (Gunnar Hejdemans Gata 29, SE) Charlotte Horsmans Poulsen (Langdalsvej 37, DK) Soren Dalsgaard (Vosnaesvej 32, DK) Huaming Wang (Fremont, CA, US) Igor Nikolaev (Offemweg 10, NL) Assignees: DUPONT NUTRITION BIOSCIENCES APS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DUPONT NUTRITION BIOSCIENCES APS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180201